NCT03732066 (WeChat) is a NA clinical trial of Usual Text Messages in Coronary Disease, sponsored by Guangdong Provincial People's Hospital.

Who is sponsoring NCT03732066?

NCT03732066 is sponsored by Guangdong Provincial People's Hospital.

What drugs are being tested in NCT03732066?

Interventions in NCT03732066: Usual Text Messages, Personalized Reminders, Interactive Responses.

What condition does NCT03732066 study?

NCT03732066 studies Coronary Disease.

Is NCT03732066 still recruiting?

NCT03732066 is currently status unknown. Last updated 26 August 2020.

Last reviewed 2020-08-26 · How we verify

NCT03732066: WeChat

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Web basEd soCial Media tecHnology to Improvement in Adherence to Dual anTiplatelet Therapy Following Drug-Eluting Stent Implantation

Status unknown NA Last updated 26 August 2020

What this trial tests

NA trial testing Usual Text Messages in Coronary Disease in 760 participants. Status unknown.

Timeline

14 January 2019

Primary endpoint
30 March 2021

30 September 2021

Quick facts

Lead sponsor	Guangdong Provincial People's Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	health services research
Enrollment	760
Start date	14 January 2019
Primary completion	30 March 2021
Estimated completion	30 September 2021
Sites	1 location across China

Drugs / interventions tested

Usual Text Messages
Personalized Reminders
Interactive Responses

Conditions studied

Coronary Disease — all drugs for Coronary Disease →

Sponsor

Guangdong Provincial People's Hospital

Who can join

18 and older, any sex, with Coronary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Few studies have attempt to improve DAPT adherence through social media. The investigators will explore the prevalence of DAPT discontinuation and prove the hypothesis that using social media will improve DAPT adherence among patients requiring DAPT following DES implantation.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Social network interventions to support cardiac rehabilitation and secondary prevention in the management of people with heart disease.
Purcell C, Dibben G, Hilton Boon M, Matthews L, et al · · 2023 · cited 17× · PMID 37378598 · DOI 10.1002/14651858.cd013820.pub2
Rationale and design of the Web-basEd soCial media tecHnology to improvement in Adherence to dual anTiplatelet Therapy following Drug-Eluting Stent Implantation (WECHAT): protocol for a randomised controlled study.
Sun GL, Lei L, Liu L, Liu J, et al · · 2020 · cited 5× · PMID 31915170 · DOI 10.1136/bmjopen-2019-033017

Verify or expand the search:

Other recruiting trials for Coronary Disease

Currently open trials in the same condition.

NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT06736899 — Trial of Orbital Atherectomy Versus Standard Strategy in Calcified Bifurcation Lesions · NA · recruiting
NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
NCT07094737 — The Italian Alliance for Cardiovascular Rehabilitation and Prevention (ITACARE-P) Registry: An Observational Study on Ca · recruiting
NCT06701968 — Effects of a Healthy Nordic Diet on Atherosclerosis in Patients with Coronary Heart Disease · NA · recruiting

Other Guangdong Provincial People's Hospital trials

Trials by the same sponsor.

NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
NCT07514611 — Weight Loss Via Intelligent Guidance in Patients With Coronary Heart Disease and Obesity: a Randomized Clinical Trial · NA · recruiting
NCT07352930 — A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Can · NA · not yet recruiting
NCT07472478 — Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12 · Phase 2 · not yet recruiting
NCT07483398 — RELIEF-PD: Crisugabalin for Nociplastic Pain in Parkinson's Disease · Phase 4 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03732066 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangdong Provincial People's Hospital
Last refreshed: 26 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03732066.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing